Key Insights

Highlights

Success Rate

87% trial completion (above average)

Published Results

127 trials with published results (26%)

Research Maturity

311 completed trials (62% of total)

Clinical Risk Assessment

Based on trial outcomes

Low Risk

Score: 17/100

Termination Rate

9.4%

47 terminated out of 498 trials

Success Rate

86.9%

+0.3% vs benchmark

Late-Stage Pipeline

29%

144 trials in Phase 3/4

Results Transparency

41%

127 of 311 completed with results

Key Signals

127 with results87% success47 terminated

Data Visualizations

Phase Distribution

405Total
Not Applicable (166)
Early P 1 (5)
P 1 (39)
P 2 (51)
P 3 (58)
P 4 (86)

Trial Status

Completed311
Unknown64
Terminated47
Recruiting31
Withdrawn19
Not Yet Recruiting16

Trial Success Rate

86.9%

Benchmark: 86.6%

Based on 311 completed trials

Clinical Trials (498)

Showing 20 of 20 trials
NCT06511141Not ApplicableRecruitingPrimary

Sacral Neuromodulation for Male Overactive Bladder (MOAB)

NCT05309993Not ApplicableWithdrawnPrimary

INvestigation of TENS Efficacy Versus Posterior Tibial Nerve Stimulation for Overactive Bladder

NCT07662824Not ApplicableRecruiting

Flyte Device for Improving Urinary Incontinence Among Endometrial and Cervical Cancer Survivors Who Have Undergone Radiation Therapy

NCT05895045Not ApplicableTerminatedPrimary

Yoga for Treatment of Overactive Bladder in Pediatric Patients

NCT07648290Early Phase 1RecruitingPrimary

Self-Start Triage Model for Post-Botox® Lower Urinary Tract Symptoms

NCT05799313Not ApplicableCompletedPrimary

Home Versus Office Removal of Percutaneous Nerve Evaluation (PNE) Lead

NCT07187466Phase 4Not Yet RecruitingPrimary

Behavioral and/or Mirabegron to Treat Urinary Symptoms in Parkinson Disease

NCT07716774Active Not Recruiting

SGLT-2 Inhibitors and Lower Urinary Tract Symptoms

NCT07693192Not ApplicableActive Not RecruitingPrimary

Comparative Efficacy and Safety if Intravesical Botulinum Toxin A Versus Platelet-Rich Plasma in the Management of Refractory Overactive Bladder : A 2 Year Study

NCT04873037Not ApplicableRecruiting

BTL Emsella Chair Versus Sham for the Treatment of Overactive Bladder

NCT05557279Phase 2CompletedPrimary

Urinary Microbiome Changes Following Administration of 500 mg of NDS-446 in Women With Dry OAB at 12 Weeks

NCT06769854Phase 4Not Yet RecruitingPrimary

Defining the Safety and Efficacy of POSterIor Tibial NeRve StimulatiON in Children

NCT05878951Phase 2Recruiting

Examining the Effects of Intra-detrusor Botox at Time of HoLEP in Men With Overactive Bladder Symptoms

NCT07432659Not ApplicableRecruitingPrimary

Add-On ZIDA Sock Therapy for Overactive Bladder

NCT06201013Not ApplicableRecruiting

Vitamin D Treat-to-Target Strategy for Children With Overactive Bladder-Wet

NCT05977634Not ApplicableActive Not RecruitingPrimary

Transcutaneous Tibial Nerve Stimulation for Idiopathic Overactive Bladder

NCT05652023Recruiting

Noninvasive Ultrasound Assessment of Detrusor Dysfunction

NCT07463326Not ApplicableEnrolling By InvitationPrimary

The Efficacy of Transcutaneous Tibial Nerve Stimulation in Women With Idiopathic Overactive Bladder

NCT06198439Not ApplicableCompletedPrimary

rTMS in Overactive Bladder

NCT06072703Not ApplicableRecruiting

Neuromodulating Cortical Regions Involved in Neurogenic Bladder in MS

Scroll to load more

Research Network

Activity Timeline